Rohit Loomba

About

Rohit Loomba is a Professor of Medicine at UC San Diego, with a focus on hepatology and gastroenterology. His educational background includes an MBBS (MD) from the Armed Forces Medical College in India, and postgraduate training through residencies and fellowships at St. Luke's Hospital and UC San Diego, respectively. His research primarily centers on non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and related liver conditions. He is involved in clinical trials and research activities aimed at non-invasive screening, diagnosis, and treatment of liver diseases, including the development of biomarkers and therapeutic options for NAFLD and MASH. Dr. Loomba has contributed to understanding the epidemiology, genetics, and clinical management of liver diseases, and his work includes leadership roles in multiple NIH-funded projects.

Research topics

• Medicine
• Internal medicine
• Gastroenterology
• Pathology
• Political Science
• Computer Science
• Biology
• Radiology
• Endocrinology
• Bioinformatics

Selected publications

• MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

  Gastroenterology · 2020 · 3222 citations

  DOI

• Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

  Nature Reviews Gastroenterology & Hepatology · 2020 · 1792 citations

  Senior authorCorresponding
  DOI

• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

  New England Journal of Medicine · 2024 · 1585 citations

  BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to r…

  DOI

• Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

  Circulation Research · 2020 · 1182 citations

  RATIONALE: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. OBJECTIVE: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19. METHODS AND RESULTS: =0.01) in patients with COVID-19 and coexisting hypertension. CONCLUSIONS: Among hospitalized…

  DOI

• Advancing the global public health agenda for NAFLD: a consensus statement

  Nature Reviews Gastroenterology & Hepatology · 2021 · 721 citations

  Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses t…

  DOI

Recent grants

• NIH Grant K23DK090303

  NIH · $721k · 2015

• Novel IL-23 inhibitor for the treatment of alcohol associated liver disease

  NIH · $3.7M · 2020–2026

• QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD

  NIH · $680k · 2015–2020

Frequent coauthors

• Claude B. Sirlin

  The University of Texas Southwestern Medical Center

  367 shared

• Arun J. Sanyal

  Virginia Commonwealth University

  345 shared

• Kris V. Kowdley

  206 shared

• Daniel Q. Huang

  National University Health System

  183 shared

• Kathryn J. Fowler

  179 shared

• Brent A. Neuschwander‐Tetri

  178 shared

• Tania Kamphaus

  Foundation for the National Institutes of Health

  166 shared

• Roberto A. Calle

  166 shared

Education

• M.D.

  University of California, San Diego

• B.S.

  University of California, San Diego

Similar researchers at University of California, San Diego

• Samir Guptah-76
• John Carethersh-68
• Peter Ernsth-64